Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 56

Results For "design"

1666 News Found

iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
Clinical Trials | June 04, 2025

iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients

The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure


Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer
Clinical Trials | June 02, 2025

Arvinas and Pfizer's Vepdegestrant significantly improves progression-free survival for patients with ESR1-Mutant, ER+/HER2- advanced breast cancer

Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer


Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows
News | June 02, 2025

Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows

Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows


ICN to organize virtual discussion on
R&D | June 02, 2025

ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4

Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals


Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer
Drug Approval | May 29, 2025

Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer

This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition


USV’s ‘United for BP Control’ Mission takes aim at India’s blood pressure epidemic
Healthcare | May 29, 2025

USV’s ‘United for BP Control’ Mission takes aim at India’s blood pressure epidemic

The initiative was announced at World Hypertension Congress, Chennai